Nephrogenic Diabetes Insipidus

Detailed Overview

Unlike central diabetes insipidus where there is a lack of ADH production, NDI involves a failure of the renal collecting ducts to respond to adequate or elevated levels of ADH. NDI can be hereditary, presenting in infancy, or acquired, most commonly due to lithium toxicity, hypercalcemia, or hypokalemia. If free water intake cannot match output, severe hypernatremic dehydration and hyperosmolar states ensue. Treatment focuses on correcting the underlying cause and paradoxically using thiazide diuretics to reduce polyuria.

Epidemiology & Demographics

Congenital NDI is rare, affecting roughly 1 in 250,000 live births (mostly males). Acquired NDI is much more common, notably affecting up to 20-40% of patients on chronic Lithium therapy.

Etiological Mechanism

Hereditary NDI is predominantly X-linked recessive due to mutations in the AVPR2 gene (encoding the V2 receptor). Less commonly, it is autosomal recessive/dominant due to mutations in the AQP2 gene (aquaporin-2 water channel). Acquired causes include Lithium use, Demeclocycline, hypercalcemia, severe hypokalemia, and chronic tubulointerstitial diseases.

Primary Causes

Lithium toxicity

Hypercalcemia

Hypokalemia

AVPR2 gene mutation (X-linked)

AQP2 gene mutation

• Chronic Lithium Therapy: Lithium enters the principal cells and interferes with the cAMP signaling pathway, downregulating aquaporin-2 expression.
• Electrolyte abnormalities: Persistent hypercalcemia (>11 mg/dL) or hypokalemia (<3.0 mEq/L) impairs medullary concentrating ability.

Normally, ADH binds to the V2 receptor on the basolateral membrane of the principal cells in the late distal tubule and collecting duct. This activates adenylyl cyclase, raising intracellular cAMP, which triggers the insertion of Aquaporin-2 (AQP2) water channels into the apical membrane, allowing water reabsorption. In NDI, this pathway is disrupted. In genetic forms, the V2 receptor or AQP2 is defective. In Lithium-induced NDI, Lithium inhibits adenylyl cyclase and glycogen synthase kinase 3 (GSK3), preventing AQP2 insertion. The collecting ducts remain impermeable to water, resulting in massive loss of free water, leading to plasma hyperosmolality and hypernatremia.

Characteristic Clinical Presentation

• Polyuria: Excretion of >3 liters (often 3-20 L) of pale urine per day.
• Polydipsia: Compensatory intense craving for water, specifically ice-cold water.
• Nocturia: Frequent waking at night to urinate, often causing severe sleep deprivation.
• Irritability and lethargy: Especially in infants with congenital NDI who cannot communicate thirst, leading to dehydration.

Physical Examination Signs

• Signs of dehydration: dry mucous membranes, poor skin turgor, tachycardia, hypotension.
• Failure to thrive (in infants).
• Altered mental status if severe hypernatremia develops.

• Severe Hypernatremia: Can lead to brain shrinkage, seizures, coma, and death.
• Hydronephrosis: Massive urine flow can dilate the ureters and renal pelvis (megacystis, megaureter) over time.
• Intellectual disability: In congenital NDI due to repeated episodes of hypernatremic dehydration in infancy.

Diagnostic Criteria & Guidelines

Diagnosis is confirmed by the Water Deprivation Test. Patient is deprived of water until plasma osmolality reaches >295 mOsm/kg. In NDI, urine remains dilute (urine osmolality < 300 mOsm/kg). Exogenous Desmopressin (DDAVP) is then administered; in NDI, there is no significant increase in urine osmolality (<50% increase), distinguishing it from central DI.

Differential Diagnosis

• Central Diabetes Insipidus
• Primary Polydipsia (Psychogenic Polydipsia)
• Diabetes Mellitus (osmotic diuresis)
• Chronic Kidney Disease

Laboratory Tests & Biomarkers

• Serum Sodium: High-normal or elevated (>145 mEq/L) if water intake is inadequate.
• Urine Osmolality: Low (< 300 mOsm/kg, often < 100 mOsm/kg) despite high plasma osmolality.
• Plasma ADH level: Normal to elevated, unlike in Central DI where it is low.

Imaging Modalities & Findings

• Renal Ultrasound:

• Compensated
  Intact thirst mechanism; patient drinks enough to match urine output. Normal serum sodium.
• Uncompensated
  Restricted water access leads to acute severe hypernatremia and dehydration.

Second-Line & Adjunctive Therapy

Amiloride (5-10 mg PO daily) is particularly useful for Lithium-induced NDI because it blocks the ENaC channels in the collecting duct, preventing Lithium from entering the principal cells. NSAIDs (Indomethacin 50 mg PO TID) inhibit renal prostaglandin synthesis (prostaglandins antagonize ADH action), increasing urinary concentrating ability.

Surgical & Procedural Management

None indicated.

Recommended Lifestyle Changes

• Unrestricted access to water at all times.
• Strict adherence to a low-sodium diet.

Patient Counseling & Advice

Educate the patient that their kidneys cannot hold onto water. They must never be restricted from drinking water. In case of illness with vomiting or diarrhea, they are at extreme risk of rapid dehydration and must seek emergency medical care immediately.

Follow-Up & Monitoring Schedule

Regular monitoring of serum electrolytes (sodium, potassium) and renal function, especially since treatment involves diuretics and NSAIDs.

Preventive Strategies

For patients on Lithium, maintain the lowest effective dose, monitor drug levels regularly, and avoid concomitant dehydration.

With free access to water and appropriate medical management, patients can lead a normal life. In congenital NDI, early diagnosis is crucial to prevent neurological damage from hypernatremia.